The FDA paused new releases of some unapproved-drug rejection letters (complete response letters, or CRLs) while it works to formalize the legal basis for disclosing the agency’s rationale. The move follows growing controversy around the policy of proactively releasing CRLs and the details underpinning the disclosures. The updated approach is expected to be anchored in a proposed legal framework slated to clarify the release of complete response letters in October. The regulatory change comes amid citizen-petition scrutiny and ongoing debate over transparency versus confidentiality in FDA decision-making. Biopharma stakeholders are watching for how the revised policy impacts communication timelines for developers, regulatory strategy planning, and investor expectations tied to CRL outcomes.